Genetic inactivation of Nupr1 acts as a dominant suppressor event in a two-hit model of pancreatic carcinogenesis

Gut. 2014 Jun;63(6):984-95. doi: 10.1136/gutjnl-2013-305221. Epub 2013 Sep 11.

Abstract

Background: Nuclear protein 1 (Nupr1) is a major factor in the cell stress response required for Kras(G12D)-driven formation of pancreatic intraepithelial neoplastic lesions (PanINs). We evaluated the relevance of Nupr1 in the development of pancreatic cancer.

Methods: We investigated the role of Nupr1 in pancreatic ductal adenocarcinoma (PDAC) progression beyond PanINs in Pdx1-cre;LSL-Kras(G12D);Ink4a/Arf(fl/fl)(KIC) mice.

Results: Even in the context of the second tumorigenic hit of Ink4a/Arf deletion, Nupr1 deficiency led to suppression of malignant transformation involving caspase 3 activation in premalignant cells of KIC pancreas. Only half of Nupr1-deficient;KIC mice achieved PDAC development, and incident cases survived longer than Nupr1(wt);KIC mice. This was associated with the development of well-differentiated PDACs in Nupr1-deficient;KIC mice, which displayed enrichment of genes characteristic of the recently identified human classical PDAC subtype. Nupr1-deficient;KIC PDACs also shared with human classical PDACs the overexpression of the Kras-activation gene signature. In contrast, Nupr1(wt);KIC mice developed invasive PDACs with enriched gene signature of human quasi-mesenchymal (QM) PDACs. Cells derived from Nupr1-deficient;KIC PDACs growth in an anchorage-independent manner in vitro had higher aldehyde dehydrogenase activity and overexpressed nanog, Oct-4 and Sox2 transcripts compared with Nupr1(wt);KIC cells. Moreover, Nupr1-deficient and Nurpr1(wt);KIC cells differed in their sensitivity to the nucleoside analogues Ly101-4b and WJQ63. Together, these findings show the pivotal role of Nupr1 in both the initiation and late stages of PDAC in vivo, with a potential impact on PDAC cell stemness.

Conclusions: According to Nupr1 status, KIC mice develop tumours that phenocopy human classical or QM-PDAC, respectively, and present differential drug sensitivity, thus becoming attractive models for preclinical drug trials.

Keywords: CANCER; ONCOGENES; PANCREAS; PANCREATIC CANCER; STRESS.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / chemistry
  • Adenocarcinoma / genetics*
  • Adenocarcinoma / pathology
  • Animals
  • Antimetabolites, Antineoplastic / pharmacology
  • Cadherins / analysis
  • Carcinogenesis / genetics*
  • Caspase 3 / analysis
  • Cell Survival / drug effects
  • Claudin-1 / analysis
  • Cyclin-Dependent Kinase Inhibitor p16 / genetics
  • DNA-Binding Proteins / genetics*
  • Deoxycytidine / analogs & derivatives
  • Deoxycytidine / pharmacology
  • Disease Models, Animal
  • Epithelial-Mesenchymal Transition / genetics
  • Gemcitabine
  • Gene Expression*
  • Genes, Suppressor / physiology*
  • Heterozygote
  • Immediate-Early Proteins / analysis
  • Life Expectancy
  • Mice
  • Mice, Knockout
  • Mucin-1 / analysis
  • Neoplasm Proteins / genetics*
  • Pancreatic Neoplasms / chemistry
  • Pancreatic Neoplasms / genetics*
  • Pancreatic Neoplasms / pathology
  • Proto-Oncogene Proteins p21(ras) / genetics
  • Signal Transduction / genetics
  • Transforming Growth Factor beta1 / analysis
  • Tumor Cells, Cultured

Substances

  • Antimetabolites, Antineoplastic
  • Cadherins
  • Claudin-1
  • Cldn1 protein, mouse
  • Cyclin-Dependent Kinase Inhibitor p16
  • DNA-Binding Proteins
  • IEX-1 protein, mouse
  • Immediate-Early Proteins
  • Mucin-1
  • Neoplasm Proteins
  • Nupr1 protein, mouse
  • Transforming Growth Factor beta1
  • muc1 protein, mouse
  • Deoxycytidine
  • Caspase 3
  • Hras protein, mouse
  • Proto-Oncogene Proteins p21(ras)
  • Gemcitabine